Figure 4. Minimal residual viremia and viral breakthrough in cases with adefovir and lamivudine resistance.
Patients 1 and 2: Adefovir resistance. Patient 3: Lamivudine resistance.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.